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Sensitization of glioblastoma 
tumor micro-environment to 
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strategy
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D. Garg  5, Patrizia Agostinis5, Véronique Mathieu6, Robert Kiss6, Florence Lefranc7, Louis 
Boon8, Jochen Belmans9, Stefaan W. Van Gool10, Holger Gerhardt3,4, Karim Amighi2 & Steven 
De Vleeschouwer1,11
In this study, we evaluated the consequences of reducing Galectin-1 (Gal-1) in the tumor micro-
environment (TME) of glioblastoma multiforme (GBM), via nose-to-brain transport. Gal-1 is 
overexpressed in GBM and drives chemo- and immunotherapy resistance. To promote nose-to-brain 
transport, we designed siRNA targeting Gal-1 (siGal-1) loaded chitosan nanoparticles that silence 
Gal-1 in the TME. Intranasal siGal-1 delivery induces a remarkable switch in the TME composition, 
with reduced myeloid suppressor cells and regulatory T cells, and increased CD4+ and CD8+ T cells. 
Gal-1 knock-down reduces macrophages’ polarization switch from M1 (pro-inflammatory) to M2 (anti-
inflammatory) during GBM progression. These changes are accompanied by normalization of the tumor 
vasculature and increased survival for tumor bearing mice. The combination of siGal-1 treatment with 
temozolomide or immunotherapy (dendritic cell vaccination and PD-1 blocking) displays synergistic 
effects, increasing the survival of tumor bearing mice. Moreover, we could confirm the role of Gal-1 
on lymphocytes in GBM patients by matching the Gal-1 expression and their T cell signatures. These 
findings indicate that intranasal siGal-1 nanoparticle delivery could be a valuable adjuvant treatment to 
increase the efficiency of immune-checkpoint blockade and chemotherapy.
Central nervous system neoplasms are subtyped in either primary or secondary brain tumors. Among primary 
brain tumors, glioblastoma multiforme (GBM) is the most prevalent high grade glioma1, 2. GBM displays highly 
necrotic, hypoxic and mitotic areas, hallmarks of high grade neoplasms3. Current therapy consists of debulking, 
followed by chemoradiotherapy, resulting in a median survival of 14.6 months4. Novel clinical treatment regimens 
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have so far had little impact on GBM patient survival5. The field of immunotherapy offers promising new avenues6 
with dendritic cell (DC) vaccinations7–10 or recent clinical trials targeting Programmed Cell Death protein-1 
(PD-1) in order to regulate the immune checkpoint in GBM (ClinicalTrials.gov identifier: NCT02335918, 
NCT02529072). Targeting PD-1 aims to release the break on the adaptive immune response against tumour cells, 
leading to increased recruitement and activation of cytotoxic T cells (CTLs).
Despite numerous clinical trials, and novel biological compounds being tested, the poor prognosis for GBM 
patients remains largely unchanged11, 12. The uniquely immune-priviledged microenvironment of the central 
nervous system proves to be particularly challenging for the efficacy of immunotherapy in GBM. Therefore, the 
development of new therapies with improved activity at the tumor site will require a deeper understanding of 
the dynamic tumor micro environment (TME) in GBM. Recent findings identified a pivotal tumour promoting 
role for Galectin-1 (Gal-1), a 14 kDa lactose binding lectin, in the TME of GBM13, 14. Gal-1 increases the migra-
tion of GBM cells and their resistance against chemotherapy (i.e. temozolomide, TMZ)15–17. Gal-1 has further 
been correlated with the proliferative gain-of-function properties of tumor cells involving anchoring the RAS 
proto-oncogene at the innerplasmatic membrane13, 18. In addition, immunosuppressive and angiogenic properties 
of Gal-1 have been suggested in the context of GBM17, 19. Rubinstein et al. noticed that blockade of Gal-1 synthesis 
in tumor cells allows the generation of a tumor-specific Th1-type immune response in vivo20. Interestingly, Gal-1 
can be upregulated in tumors during radiotherapy, thereby sustaining immune suppression21. These features pin-
point Gal-1 as a crucial molecule in shaping the TME in GBM. Indeed, intraventricular delivery of siGal-1 can 
sensitize GBM cells to TMZ while reducing the abnormal tumour vasculature17. However, the invasive procedure 
of intraventricular administration is associated with inherent adverse events such as inflammation.
As a non-invasive alternative route to deliver therapeutic agents into the central nervous system, and more 
specifically into the TME of GBM, we proposed the nose-to-brain transport via intranasal administration22. In 
recent years, the intranasal transport towards the central nervous system has gained a lot of momentum, and 
even reached the clinical stage because of patient comfort and reduced adverse secondary effects23–25. Previously 
we described that chitosan nanoparticles are able to transport siGal-1 to the TME in GBM26. This leads to a 
specific degradation of Gal-1, while other galectines (such as Gal-3) are not affected. After administriation in 
the nasal cavity, siGal-1 is rapidly transported to the olfactory bulbus and spread within the inoculated glioma 
TME. Functionally, we observed a strong reduction of Gal-1 after siGal-1 treatment and subsequent cleaved Gal-1 
mRNA fragments in GL261 glioma tumors. As such, we were able to provide strong evidence for in vivo RNAi 
mediated targeted reduction of Gal-1 via the intranasal pathway.
Here, we investigated the consequences of reducing Gal-1 in the TME during the GBM progression on both 
myeloid and lymphoid compartments of the immune system. Moreover, we evaluated the effect of Gal-1 siRNA 
therapy alone or in combination with chemotherapy or immunotherapy using DC vaccination and PD-1 block-
ade on survival of glioma bearing mice. The relevance of our findings were confirmed by the comparison of 
the Gal-1 knock-down signatures in our GBM model with GBM patients data from The Cancer Genome Atlas 
(TCGA) database. Our findings identify Gal-1 as a key regulator of the TME that drives resistance towards con-
ventional chemotherapy and explorative immunotherapy. Nose-to-brain delivery to modulate the TME is an 
underexplored treatment modality and beholds great promise for GBM patients, especially when combined with 
chemo- and immunotherapy.
Results
siGal-1 treatment improves survival in GL261 tumor bearing mice by altering the tumor 
micro-environment. To confirm our previous findings, we first verified the reduction of Gal-1 after siGal-1 
administration (Supp. Fig. 1). Gal-1 is reduced whithin the tumor micro-environment by about 40%. In previ-
ously published results we observed that reducing gal-1 expression can inhibit the migration and/or proliferation 
pattern of GL261 murine GBM cells in vitro26. Stimulated by the existing literature on siGal-1 in GBM, we inves-
tigated possible survival benefits in GL261 tumor bearing mice. First, we asked whether intranasal siGal-1 as 
monotherapy could improve survival (+siRNA, Fig. 1A). We observed a significant shift in survival when siGal-1 
loaded chitosan nanoparticles were administered during GBM progression. A small shift of 2.5 days in median 
survival, and more importantly, about 20% long-term survival was induced. Scrambled siRNA incorporated in 
chitosan nanoparticles or empty chitosan nanoparticles (+scrambled siRNA and -siRNA, Fig. 1A) had no effect 
on survival. To further delineate the consequences of siGal-1 treatment, we hypothesized that the prolonged 
survival could be explained either by a direct decreased proliferation of GL261 tumor cells, or by complemen-
tary TME re-arrangement. We first quantified Ki67+ staining to measure tumor proliferation. Proliferation was 
significantly decreased during siGal-1 treatment, while scrambled siRNA loaded chitosan nanoparticles had no 
effect on GL261 (Fig. 1B, representative pictures Supp Fig. 2). Of note, the inhibitory effect was already pro-
nounced at day 12 post tumor inoculation, indicating a rapid delivery and onset of siGal-1. Caspase3 staining 
revealed no changes in apoptosis (Supp Fig. 3). To analyse the cellular composition of GL261 TME, a thorough 
examination of the macrophage populations was performed (Fig. 1C). Macrophages are one of the most abun-
dant cell types present in the TME of GBM. They can be polarized as either M1 (MHCIIhigh) or M2 (MRChigh) 
corresponding to pro-inflammatory and anti-inflammatory phenotypes, respectively27. Gal-1 siRNA treatment 
induced a shift in these macrophage phenotypes: reduction of Gal-1 did not affect the total pool of macrophages, 
but effectively reduced the transition from M1 to M2 polarization (Fig. 1D). Scrambled siRNA did not affect 
macrophage polarization.
siGal-1 treatment modulates myeloid and lymphoid cells during GBM progression. We next 
assessed whether Gal-1 expression is linked to changes in the myeloid compartment of TME infiltrating leu-
kocytes. Using flow cytometry, we observed a reduction in CD11b+ leukocytes from 37 to 28% in response to 
siGal-1 intranasal administration (Fig. 2A; gating strategy Supp Fig. 4). Further subtyping revealed that this 
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Figure 1. siGal-1 monotherapy in GL261 tumor bearing mice elicits a survival benefit, and a re-arrangement 
of tumor micro-environment. Mice were inoculated with 0.5 × 106 GL261 cells which induce a lethal GBM 
after 15–20 days. (A) Survvial analysis of mice which were left untreated (clear dots), treated with siGal-1 
on day 4, 8, 12 and 15 after tumor inoculation (red squares), or treated with empty nanoparticles (without 
siRNA, black dots) or treated with scrambled siRNA loaded chitosan nanoparticles (scrambled siRNA, black 
triangles). (B) Quantification of proliferation assay measured by Ki67+ staining. Monotherapy siGal-1 revealed 
a significant Ki67+ proliferation decrease in GL261 gliomas, in early and late stage (early stage = day 12 after 
tumor inoculation; 2 administrations, at day 4 and 8/at late stage GBM = day 20 after tumor inoculation, with 4 
administrations at day 4, 8, 12 and 15), as compared to controls, untreated or scrambled siRNA loaded chitosan 
nanoparticles (n = 4/group, *p < 0.05 and ***p < 0.001). (C) Immunofluorescence pictures of TME, stained 
for total macrophages (F4/80+), M1 macrophages (MHCII+) and M2 macrophages (MRC1+), obtained 
from untreated control mice, scrambled siRNA loaded chitosan nanoparticles treated mice, or siGal1 treated 
mice. These pictures indicate that the total amount of macrophages in the TME is not affected, but merely 
the polarization of M1 to M2 polarization. MRC1+M2 macrophages are reduced with siGal-1 therapy, as 
compared to untreated or scrambled siRNA treated mice. (D) Quantification of multiple sections of several 
mice (n = 4/group), indicates the effect is most pronounced at late stage GBM (day 20 after tumor inoculation, 
with 4 administrations at day 4, 8, 12 and 15), whereas in early stage (day 12 after tumor inoculation; 2 
administrations, at day 4 and 8) these differences were less pronounced. Black bars represent treated mice, white 
bars are untreated controls, and gray bars are treated with scrambled siRNA loaded chitosan nanoparticles; 
groups were compared via two way ANOVA, with Bonferroni post test as compared to control and scrambled 
siRNA (n = 4/group, ***p < 0.001). Scale bar: 75 µm.
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reduction was mainly caused by a reduction in immune suppressive monocytic myeloid derived suppressor 
cells (MDSCs) defined as Ly6C+CD11b+ leukocytes from 26 to 20%. The percentage of granulocytic MDSCs 
(Ly6G+CD11b+) appeared unaffected. Besides MDSCs in the TME, also macrophages can exert immune 
suppressive functions. As described above, macrophages can be subtyped in M1 (MHCIIhigh, MRC−) or M2 
(MHCIIlow,MRC+) of which the latter are known to reduce inflammation and negatively affect the prognosis in 
Figure 2. siGal-1 alleviates immune suppression and induces immune activation during GBM progression. 
Flow cytometry was performed on isolated mononuclear brain infiltrating cells of mice that were left untreated, 
or treated with siGal-1 on day 4, 8, 12 and 15 after tumor inoculation, and brains were isolated at day 20. 
Different stainings assess several cell populations with (A) the myeloid cells, with monocytes as gated by ZY−, 
CD45+, CD11b+; monocytic MDSCs as ZY−, CD45+, CD11b+, Ly6C+; M1 macrophage phenotype as 
CD45+, CD11b+, ZY−, MRC−, MHCIIhigh; M2 macrophage phenotype as CD45+, CD11b+, ZY−, MRC+, 
MHCIIlow. (B) The lymphoid cells with leukocytes, as single cells, ZY−, CD45+; lymphocytes as single cells, 
ZY−, CD45+, CD3+, CD4 lymphoctyes as single cells, ZY−, CD45+, CD3+, CD4+; Th1 as single cells, ZY−, 
CD45+, CD3+, CD4+, IFNγ+ gated to CD45+; CD8 lymphocytes as single cells, ZY−, CD45+, CD3+, 
CD8+; CTL as single cells, ZY−, CD45+, CD3+, CD8+, IFNγ+ gated to CD45; Tregs, as gated by single cells, 
ZY−, CD45+, CD3+, CD4+, FoxP3+; (C) the ratio immune activation to immune suppression was calculated 
for Th1 (IFNγ+CD4+CD3+CD45+ZY−) and (D) CTL (IFNγ+CD8+CD3+CD45+ZY−), as compared 
to Treg (FoxP3+CD4+CD3+CD45+). White bars represent the siGal-1 treated mice, black bars are control 
tumor bearing mice and groups were compared with unpaired t-test (n = 5/10 per group, *p < 0.05, **p < 0.01).
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GBM. Flow cytometry analysis confirmed that the reduction of Gal-1 promotes the M1 phenotype, and prevents 
the M2 phenotype (Fig. 2A).
As the immune suppressive myeloid cells compartment was altered by Gal-1 siRNA treatment, we analysed 
the lymphoid counterpart and monitored the regulatory T cell population (Treg). Both at the mRNA and protein 
level, we detected a decrease of FoxP3+ cells, a Treg specific transcription factor (Fig. 2B + Supp Fig. 5; gating 
strategy Supp Fig. 6). Together these data indicate a general reduction of immunosuppression in GBM, in both 
the innate and adaptive arm of immunity, when gal-1 expression is diminished.
On the other side of the spectrum, we have investigated the immune stimulatory mediators in GBM. Overall, 
we found a decrease in leukocytes (CD45 + viable cells; Fig. 2B; gating strategy Supp Fig. 7), which we attribute 
to the decrease in overall myeloid MDSCs. Further co-staining revealed a significant increase in CD3+ lympho-
cytes (Fig. 2B). Specifically, we found a general increase in T helper lymphocytes (Th, CD4+CD3+lymphocytes), 
and cytotoxic T cells (CTL, CD8+CD3+lymphocytes). These cells appeared not only increased in number, but 
also in function, as measured by their interferon–gamma (IFNγ) production, indicated as Th1 (CD4+) and CTL 
(CD8+) lymphocytes relative to the total amount of leukocytes (Fig. 2B). As we observed an increase in Th1 and 
CTL response, and a decrease in Treg population, the ratio of immune activation to immune suppression was 
clearly shifted in favor of activation (Fig. 2C+D). Taken together, these data indicate that siGal-1 treatment can 
induce an alleviation from the immune suppression, while increasing the immune activation.
siGal-1 therapy synergizes with TMZ and PD-1 blocking. To our understanding, siGal-1 treatment 
should be applied as an adjuvant therapy that synergizes with existing treatment schedules. As mentioned before, 
reducing gal-1 expression has been shown to improve the efficacy of chemotherapeutic drugs such as TMZ in 
GBM bearing mice17. Also in our GL261 model, after three administrations of 40 mg/kg, we observed a significant 
median survival shift for glioma bearing mice, from 19 days in untreated mice, to 32 days in TMZ treated mice 
(Fig. 3A). Combining the intranasal siGal-1 administration and per os TMZ administration resulted in a syner-
gistic survival benefit. In the combination therapy, the median survival increased from 32 days in TMZ treated 
mice, to 53 days in siGal-1 and TMZ treated mice. We also observed a long-term survival of 40% after combina-
tion therapy, compared to about 20% under monotherapy. These results indicate that reducing gal-1 expression 
could be applied as an adjuvant treatment modality to TMZ administration.
Given that reducing gal-1 expression alone could shift the balance from immune suppression to activation, 
resulting in a modest survival benefit (Fig. 1A), combining siGal-1 with other immunotherapies seemed appeal-
ing. Therefore we started with a prophylactic vaccination model established in our facilities28. Mice were vacci-
nated two weeks before tumor inoculation with lysate pulsed DC vaccines which results in strong anti-tumoral 
immunity as indicated by the survival benefit of 20.5 days in untreated mice, to 42 days in DC vaccine treated 
mice (Fig. 3B). We observed that combining DC vaccine with siGal-1 further pushed the significance level, 
and increased the median survival to 53 days with about 30% long-term survival. No statistical difference was 
observed between DC vaccine and the combination therapy, largely attributed to the heterogeneous effect of DC 
vaccine. As a second immunotherapy approach, we tested immune checkpoint blockade by means of PD-1 block-
ing in established brain tumors. Intraperitoneal injection of anti-PD-1 antibody increased the survival from 17.5 
days in untreated mice, to 30 days in anti-PD-1 treated mice (Fig. 3C). Concomitant intranasal administration of 
siGal-1 profoundly improved the therapeutic effect of anti-PD-1 administration, resulting in a median survival of 
51.5 days and about 20% long term survival.
To quantify the effect of the combination regimens with siGal-1, TMZ, DC vaccination and PD-1 blocking, 
we used the Robert Clarke Equations, that can discriminate between additive or synergistic effects (Fig. 3D)29. 
Calculation revealed an additive effect of DC vaccination and siGal-1 combination, and a synergistic effect of 
siGal-1 with either TMZ treatment or with PD-1 blocking antibody injection.
We conclude from these data that siGal-1 therapy is effective in a rational combination with chemo- and 
immunotherapy.
Mechanistic insight into synergistic effects of siGal-1. We observed a small survival benefit for mice 
that received monotherapy siGal-1 (Fig. 1A) and a strong synergistic effect of reducing gal-1 expression in com-
bination with chemo and immunotherapy. Therefore, we tried to elucidate the underlying mechanisms driving 
the synergy. We noticed that blood vessels in the tumor bearing mice that were treated with siGal-1 appeared less 
dilated and tortuous than in untreated mice (Fig. 4A). In untreated control mice, the tumor vasculature typically 
features dilated and non functional vessels whereas gal-1 targeting therapy significantly normalizes vessel caliber 
(Fig. 4B). Scrambled siRNA however does not normalize the vasculature in GBM (compare vessels in Fig. 1C). 
Chaotic TME blood vessels typically result in a poor tissue perfusion. We therefore hypothesized that TMZ could 
reach a larger tumor area if vessels were normalized to some extent30. To observe the distribution pattern of TMZ, 
we performed immunohistochemistry labelling phospho-H2aX to highlight double strand break DNA damage 
(Fig. 4C and D). Equal dose of TMZ induced more widespread DNA damage after pre-treatment with siGal-1, 
consistent with the observed normalization of the tumour vasculature.
To elucidate the synergy between siGal-1 and anti-PD1 therapy, we performed flow cytometry analysis of 
tumor infiltrating lymphocytes. We observed that anti-PD1 therapy effectively reduced the expression of PD-1 
on CD4+ and CD8+ lymphocytes in the glioma TME (Fig. 4E), but no additional effects of combined siGal-1 
treatment. Next, we observed that the ratio between Th1 response and Treg, or CTL and Treg, was increased upon 
anti-PD-1 therapy, and even more pronounced in combination therapy (Fig. 4F and G). These data, together with 
the survival benefits (Fig. 3C), indicate that anti-PD1 therapy by itself can stimulate the immune activation, and 
also that siGal-1 therapy can further increase the immune stimulation.
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LGALS1 facilitates immunosuppressive T cell milieu in glioblastoma tumor tissue. Our pre-
clinical results indicated that Gal-1 promotes immunosuppression within the GBM TME and as such, targeting 
it helps shift the TME towards an anti-tumorigenic Th1/CTL-based immune contexture. Therefore, we wanted 
to validate whether Gal-1 (coded by the gene LGALS1) also facilitates immunosuppression of T cells within the 
GBM TME of human patients. We deemed such analysis crucial for translational positoning and prioritization of 
this siGal-1 therapy for GBM patients in the near future.
Figure 3. Survival benefit of siGal-1 in combination with chemo- and immunotherapy. Mice were inoculated 
with 0.5 × 106 GL261 cells which induce a lethal GBM after 15–20 days. Combination strategy with (A) 
TMZ was organized by siGal-1 administration at day 2, 4, 7 and 11 after tumor inoculation prior to TMZ 
administration at day 8, 11 and 15, at a dose of 40 mg/kg. For combination with immunotherapy, DC 
vaccination (B) and PD-1 blocking (C) were included. In (B), mice received monotherapy siGal-1 as described 
in Fig. 1A (open red squares), prophylactic DC vaccination at day −14 and −7 before tumor inoculation (200 µg 
lysate/million DCs, IP, black dots), or the combination of DC vaccination and siGal-1 (closed red squares). In 
(C), mice received anti-PD-1 mAb at day 7 and 12 after tumor inoculation (100 µg/day, IP, black dots) or the 
combination of PD-1 blocking and siGal-1 (closed red squares). Curves were compared by Log-Rank survival 
analysis. (n = as indicated, *p < 0.05, **p < 0.01 and ***p < 0.001). (D) Based on median survival data (from 
Fig. 3A,B and C), the calculations for antagonistic effect, additive effect and synergistic effect were carried 
out based on the Robert Clark Equations29; where A = response to treatment 1 (=siGal-1), B = response to 
treatment 2 (=TMZ, DCvacc or anti-PD-1), AB = combination groups and C = response to no treatment 
(=control).
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Figure 4. Mechanistic insights explaining synergistic effects of siGal-1 with chemo and immunotherapy. 
Mice were inoculated with 0.5 × 106 GL261 cells which induce a lethal GBM after 15–20 days. (A) Mice 
were left untreated (left panel), treated with siGal-1 on day 4, 8, 12 and 15 after tumor inoculation (right 
panel), and stained for GLUT-1 (red), which stains vasculature. (B) Quantification revealed signficantly 
enlarged vasculature in untreated mice. (n = 5/group, **p < 0.01). (C) TMZ induced DNA damage was 
measured by phospho-H2AX staining (green), which (D) indicated a significant higher DNA damage 
pattern if mice were pre-treated with siGal-1. (n = 3/4/group, **p < 0.01). (E) Analysis of brain infiltrating 
lymphocytes during anti-PD-1 therapy (at day 7 and 12 after tumor inoculation, 100 µg/day), at day 18 post 
tumor inoculation, revealed a significant decrease of PD-1 expression on CD4+ (black bars) and CD8+ 
(gray bars) lymphocytes. In (F) the ratio immune activation to immune suppression was calculated for Th1 
(IFNγ+CD4+CD3+CD45+ZY−) and CTL (G) (IFNγ+CD8+CD3+CD45+ZY−), as compared to Treg 
(FoxP3+CD4+CD3+CD45+). (n = 5/group, *p < 0.05 and **p < 0.01). Scale bar: A. 100 µm; C. 250 µm.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 1217  | DOI:10.1038/s41598-017-01279-1
High-powered genetic analysis of human tumor-associated T lymphocytes (TILs) in publicly available 
big-datasets like The Cancer Genome Atlas (TCGA) can be achieved through the emerging technique of using 
(pre-established) T cell-specific gene signatures or metagenes31–33. To this end, we utilized recently established T 
cell-specific metagenes tailored for human GBM12 and first estimated GBM patient survival based on a ratio of 
Th1-to-Treg and CTL-to-Treg to estimate the prognostic impact of a Th1/CTL vs. Treg based immune contexture.
In line with previous observations12, TCGA GBM patients exhibiting higher expression of Th1/Treg 
metagene-ratio (i.e. more Th1 expression and less Treg expression) (Fig. 5A) and CTL/Treg metagene-ratio 
(Fig. 5B), had prolonged overall survival (OS) compared to corresponding low expression groups, as indi-
cated by hazard ratios (HRs; 0.83 (0.66–1.05) for Th1/Treg metagene-ratio and 0.81 (0.64–1.03) for CTL/Treg 
metagene-ratio). This reiterates the importance of a Th1/CTL-based immune contexture over a Treg-based 
immune contexture for cancer patients12, 34.
Interestingly, GBM patients exhibiting high expression of GBM-associated LGALS1 tended to show subtan-
tially reduced OS compared to patients possessing LGALS1Low GBM tumors (Fig. 5C). In line with previous 
studies13, 35, 36, these findings confirm (at the TCGA-level) our observation of Gal-1 being a pro-tumorigenic 
factor. However, Gal-1 has several functions within the tumor, not only in glioma cells but also in stromal or 
immune cells. With respect to our preclinical data and the clinical analysis above, it was necessary to ascertain the 
exact association of LGALS1 with Th1/Treg and CTL/Treg ratios. Interestingly, LGALS1 gene expression showed 
a highly significant negative correlation with the Th1/Treg (Fig. 5D) and CTL/Treg (Fig. 5E) metagene-ratios 
within the TCGA GBM cohorts. These results would be in line with a role for higher LGALS1 expression facilitat-
ing the accumulation of Treg over Th1/CTL in GBM.
In conclusion, our TCGA GBM clinical data analysis suggests that LGALS1 facilitates the maintenance of a 
immunosuppressive Treg-based tumoral environment.
Discussion
Understanding the cellular and molecular dynamics in the TME of malignancies such as GBM is a prerequisite for 
the development of effective non-invasive therapies. Our current work focused on Gal-1 as an important driver 
for the inherent resistance against chemo- and immunotherapy in GBM biology. Specifically, we demonstrate 
that, by using the nose-to-brain transport, we are able to suppress gal-1 expression in the TME, which results in 
a shift from immune suppression to immune activation. Our intranasal approach to block gal-1 expression in 
GBM confirms the previous benefitial findings that were however obtained by much more invasive approaches 
not translatable to the clinic. Moreover, we could demonstrate synergistic effects with novel immunotherapeutic 
agents as PD-1 blocking agents, which gives additional arguments why nose-to-brain transport to reduce gal-1 
expression could represent a valuable adjuvant therapy. In the present study, we explored the potential of chitosan 
nanoparticles to promote the nose-to-brain delivery. In part, these particles were selected due to the ease of man-
ufacturing, the gentle production process and the proven transport into the central nervous system. In a recent 
literature report, chitosan coated lipid nanocapsules have been proven to effectively silence Gal-1 and EGFR in 
GBM, which also sensitizes GBM to TMZ treatment37. To this end, both lipid-based and polymeric based formu-
lations can have beneficial effects, and are demonstrated to posses effective RNAi delivery efficiency.
In a syngenic, orthotopic murine model for GBM, we provide evidence that reducing gal-1 expression induces 
a significant survival benefit. We observe a shift in median survival, and a long term survival induction of 20%. 
Especially the induction of long term survivors is intriguing, which coincided with remarkable changes in the 
microenvironment. Moreover, we demonstrate a decreased Ki67 proliferation in siGal-1 treated GL261 gliomas. 
In a previous report, we demonstrated that we are able to decrease gal-1 expression in the TME by 50% as meas-
ured by western blot analysis26. Despite this robust decrease of Gal-1, the survival benefit in monotherapy is only 
modest, which already implies that siGal-1 should be considered as a sensitization tool to increase the efficiency 
of existing treatment modalities. To analyse the cell composition of the GBM TME, we dissected the macrophage 
population during GBM progression. We demonstrate the inhibition of polarization from M1 macrophages to 
M2 macrophages during GBM progression, when treated with siGal-1. Activation of the M2 phenotype has 
been shown to worsen the prognosis and aggravate disease through secretion of vascular promoting factors such 
as VEGF-A, and immune suppressive factors such as TGF-β and IL-10. This macrophage population relocates 
around TME associated vessels to form perivascular cuffs and further drives vascular abnormalities (Mathivet 
T. et al.; Dynamic stroma reorganization drives blood vessel dysmorphia during glioma progression; under revi-
sion). Therefore, a decrease in M2, but also in CD11b monocytes, and specifically the monocytic MDSCs, can 
already relieve a major fraction of the immune suppressive nature of the TME38. In recent years, it has been 
suggested that there is an intensive crosstalk between the immune suppressive actors of the myeloid side and of 
the lymphoid arm of the immune system. We also find a decrease in FoxP3+ Treg cells in the TME when Gal-1 
is reduced. Whether this effect is mediated by a myeloid-lymphoid interaction or a direct effect of Gal-1 remains 
unclear39. The presence of Gal-1 and the recruitment of FoxP3+ Treg cells has already been established in previous 
reports40, 41. Not only do we find evidence for alleviation of immune suppression upon siGal-1 treatment, but also 
for promoting immune activation. CD3+ lymphocytes are increased within the TME upon Gal-1 reduction, and 
more specifically, both Th1 and CTL infiltrate the GBM. It has been demonstrated that GL261 cells upon IFN-γ 
stimulus, can up regulate MHCI molecules, and thereby are more susceptible to CD8+ mediated destruction12. 
These findings are in line with the proposed role of Gal-1 that drives apoptosis in activated T cells when reaching 
the TME42.
In further functional testing of our intranasal siGal-1 approach, we do not consider siGal-1 therapy as a 
monotherapy, but rather as an adjuvant therapy, which can be combined with chemo- and immunotherapy. 
Combination therapy of intranasal siGal-1 (at a dose of 1 unit at day 2, 4, 7 and 11) and per os temozolomide (at a 
dose of 40 mg/kg at day 8, 11 and 15) elicits a significant synergistic survival benefit. The shift in median survival 
was similar to that described previously, with intratumoral and intraventricular siGal-1 injections17, although in 
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Figure 5. Analysis of association between T cell-associated genetic signatures and LGALS1 in human 
glioblastoma (GBM) patients. (A) The ratio of genetic signatures or metagenes specific for Th1 and Treg was 
used to stratify the The Cancer Genome Atlas (TCGA) GBM patients into “high Th1/Treg ratio” (red) or “low 
Th1/Treg ratio” groups; followed by Kaplan-Meier plotting of patient’s overall survival versus follow-up duration 
in days. (B) The ratio of genetic signatures or metagenes specific for CTLs and Treg was used to stratify the 
TCGA GBM patients into “high CTL/Treg ratio” (red) or “low CTL/Treg ratio” groups; followed by Kaplan-
Meier plotting of patient’s overall survival versus follow-up duration in days. (C) The differential expression of 
LGALS1 was used to stratify the TCGA GBM patients into “high expression” (red) or “low expression” groups; 
followed by Kaplan-Meier plotting of patient’s overall survival versus follow-up duration in days. In A–C graphs, 
log-rank (Mantel-Cox) test p-values and hazard ratios (HR) with 95% confidence interval (in paranthesis) 
are displayed. Alternatively, a Pearson’s correlation coefficient was calculated to assess the overall association 
between LGALS1 expression and overall expression of either Th1/Treg ratio (D) or CTL/Treg ratio (E).
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previous studies no long-term survivors were observed, most likely due to the use of nude-mice, and therefore 
lacking an immune component. This underlines the bio-equivalence of the non-invasive intranasal pathway, in 
comparison with more aggressive, invasive therapies. We observed that treatment with siGal-1 can reduce the 
vascular diameter in the TME from 15 µm to 10 µm. Previous reports describe how tumor derived Gal-1 can 
enhance endothelial function in migration and proliferation potential43, or even complement VEGF signaling44, 45. 
This reduction can be either attributed to the reduction in M2 (and lack of VEGF-A secreted in the perivascular 
spaces), or to direct anti-angiogenic effects of siGal-1. Therefore, the pre-treatment with siGal-1 could improve 
TMZ delivery through better tumor vessel perfusion in the entire TME, thus reaching the tumor mass in toto. We 
provide a functional experimental read-out in showing aggrevated and widespread DNA damage, which is not 
necessarily the result of enhanced perfusion, but supports the hypothesis. On the other hand, the reduction of 
Gal-1 obtained with siGal-1 pre-treatment alters the unfolded protein response to endoplasmatic reticulum stress, 
increasing thereby the inherent sensitivity of GBM cells to TMZ delivered17. Accordingly, in other, non-reported 
experiments, where siGal-1 therapy was administered concomitantly or later in the dosing schedule, we did not 
observe this synergy. This dose regimen optimization supports the hypothesis that siGal-1 should be delivered 
prior to TMZ administration. Assessment of the aggravated DNA damage induced by alkylating chemotherapy in 
the combination demonstrates that more tumor tissue is affected by administration of TMZ, as pointed out by the 
increase of phospho-H2aX histone complexes. This increase results in G2/M arrest46. Interestingly, TMZ is also 
reported to have anti-angiogenic properties, which might attribute to the observed synergistic effects between 
siGal-1 and TMZ47. In this study, TMZ was discovered to impair angiogenic processes, leading to strong survival 
benefits of human xenograft models when combined with bevacizumab. Interestingly, in a recent clinical trial 
report, TMZ showed unexpected immune-modulating activity48. Low-dose regimen TMZ could actively suppress 
regulatory T cells patients with advanced melanoma. We therefore speculate that siGal-1 and TMZ can work 
together to actively decrease the regulatory T cell population, and prevent further tumor progression. Alternative 
combination treatments can be found in the field of immunotherapy. In a first approach, we tested a DC vaccina-
tion strategy developed in our laboratory, as a potent prophylactic immunotherapy in the murine GL261 model. 
In the tested dosing combination, we could only observe non-significant additive survival benefit upon Gal-1 
reduction. However, with immune checkpoint inhibition via PD-1 blockade, combination therapy leads to a syn-
ergistic survival benefits in mice with established brain tumors. We also find an increased immune stimulation of 
lymphocytes in the TME in the combination treatment, as compared to PD-1 blocking alone. Of note, aberrant 
vasculature in tumors is suggested as a substantial barrier for the extravasation of T cells38. As siGal-1 could effi-
ciently reduce the vascular abnormalities, this could potentially explain the influx of Th1 and CTL. According to 
Robert Clark Equations, we observed a synergistic effect of combining anti-PD-1 therapy and TMZ therapy with 
siGal-1, and an additive effect of DC mediated immunotherapy in combination with siGal-1 (Fig. 3D). Adjuvant 
therapies such as siGal-1 therapy might therefore represent valuable approaches to further increase the efficiency 
of anti-PD-1 and TMZ therapy.
To validate our findings, we correlated the murine data with their human TCGA patient counterpart. Also in 
human samples, we found a clear correlation between lower Gal-1 and immune activation. Patients with lower 
Gal-1 had a more favorable Th1/Treg or CTL/Treg balance, which reflects in a better prognosis, as demonstrated 
by hazard ratios. Murine models have many advantages, but also inherent limitations. By demonstrating the 
translatability of Gal-1 biology on T cells from murine to human samples, we confirm the potency of Gal-1 as a 
driver of immune suppression during GBM progression.
In our research, we have elaborated on several key features of GBM tumor progression that are driven by Gal-1 
biology. We have addressed proliferation, angiogenic, immunological, and TMZ-resistance properties of GBM 
after targeting gal-1 expression via intranasal siRNA delivery. This research is a first step to pave the way towards 
a clinical implementation of the nose-to-brain transport of siGal-1 in the current treatment schedule of GBM 
patients. To our knowledge, this is the first report where the aforementioned pathway is validated from phar-
maceutical development, to biological efficacy in a GBM tumor model. Moreover, as PD-1 blocking is currently 
being tested in clinical trials for GBM, we provide a method to augment its efficacy via a combination with this 
transnasal siGal-1.
Materials and Methods
Animals and treatments. International ethical guidelines were followed and approved by the bioethics 
committee at KU Leuven. Tumor inoculations were performed as described previously26. In brief, 0.5 × 106 
GL261 cells were stereotactically injected in the striatum of 8–10 weeks old C57Bl/6 mice (C57BL/6JOlaHsd, 
Harlan,The Netherlands). GL261 cells were received as a gift from Dr. Eyupoglu, University of Erlangen, 
Germany. Long term survival was defined as exceeding 3 x median survival of untreated control mice. Intranasal 
siGal-1 administrations were administered as 8 droplets of 3 µl with a non-adhesive micropipette tip (Eppendorf). 
Total amount of 1 administration was defined by 48 µg siRNA/dose and chitosan nanoparticles composition 
as described before26. In brief, chitosan nanoparticles were prepared by ionic gelation of tripolyphosphate and 
chitosan, while adding siRNA. Consequently, particles were collected by ultracentrifugation at 40000 × g dur-
ing 3 cycles of 20 min, and freeze-dried with sucrose as lyoprotectant. At the indicated time points, chitosan 
nanoparticles were administered intranasally, under 3% isoflurane anesthesia. Mice that received intranasal PBS 
(control) or chitosan nanoparticles, experienced shivers and extensive grooming after anesthesia, followed by 
a small weight loss (1–2 g) the next day, due to the isoflurane administration of typically about 30 min/mouse. 
This weight loss quickly recovered, although in the 3th week after tumor inoculation, mice start to loose weight 
due to tumor burden. Sequences: siGal-1 5′ACCUGUGCCUACACUUCAAdTdT3′) and scrambled siRNA 
(5′GGAAAUCCCCCAACAGUGAdTdT3′) were purchased from GE Dharmacon.
TMZ administrations were performed as described previously12. In brief, Temodal capsules were opened and 
dissolved in a phosphate buffer, with an equal amount of L-Histidine, and administered in a total volume of 200 µl 
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by gavage (Schering-Plough, Belgium). For survival experiments mice received 40 mg/kg TMZ at day 8, 11 and 
15 post tumor inoculation. For phospho-H2AX assessments, mice received 80 mg/kg TMZ at day 13 and 14 post 
tumor inoculations, and were sacrificed for immunostainings 4 h after the last administration.
DC vaccinations were performed as described previously28. In brief, 200 µg irradiated lysate was loaded per 
1 × 106 immature DCs. Subsequently DCs were pulsed towards mature DCs with LPS, settled for 24 h, and intra-
peritoneal administered at day 14 and day 7 prior to tumor inoculation. Anti-PD-1 antibodies (RMP1-14) and 
isotype controls (Rat IgG) were dissolved in saline (Braun, The Netherlands) and intraperitoneal administered at 
day 7 and 12 post tumor inoculation (100 µg/administration, Epirus Biopharmaceuticals).
Flow cytometry. Flow cytometric analysis was performed as described earlier12. In brief, animals were sac-
rificed by lethal injection of Nembutal at the indicated time points, and perfused with PBS (Lonza, Belgium). 
Single cell suspensions were obtained after mincing with scalpels and 30′ incubation with DNase (Invitrogen) 
and CollagenaseD (Roche). Mononuclear cells were separated from debris via Percoll gradient centrifugation 
(Sigma), and the intermittent layer was washed twice with PBS. Surface stainings were performed with antibodies 
as mentioned in Table 1.
The intracellular detection of FoxP3 was performed using a FoxP3 staining kit (eBioscience, San Diego, CA) 
according to the manufacturer’s protocols. For intracellular IFN-γ staining, cells were stimulated for 4 h with 
100 ng/ml phorbol myristate acetate, 1 µg/ml ionomycin and 0.7 µg/ml monensin. Cells were fixed in 1% PFA for 
15 min. and resuspend in 0.5% PBS/BSA until acquiring by cytometer (LSRFortessa, BD). Cell population analysis 
was performed with FlowJo.
Immunofluorescence staining. Immunofluorescence staining was performed on mouse brain vibratome 
sections as described earlier26. Following primary and secondary antibodies are summarized in Table 2. White 
bars represent 50 µm.
Aqcuisition was performed on Leica SP8 confocal microscope and analyzed via Adobe Photoshop and ImageJ 






MHCII PerCP Cy5.5 Biolegend
Mannose Receptor PE Biolegend
Isotype Rat IgG2a,k PE Biolegend
Live/dead Zombie Yellow Biolegend
CD3 FITC/PE Ebioscience





IFN-γ PerCP Cy5.5 BD
Table 1. Flow cytometry antibodies.
Antigen/Primary Antibody Origin Secondary Antibody Origin
GLUT-1 Millipore Donkey Anti-rabbit Alexa 555 Life Technologies
GLUT-1 Abcam Donkey Anti-mouse Alexa 555 Life Technologies
GLUT-1 Santa Cruz Donkey Anti-goat Alexa 555 Life Technologies
Gal-1 Peprotech Donkey Anti-rabbit Alexa 647 Life Technologies
F4/80 Life Technologies Donkey Anti-rat Alexa 488 Life Technologies
MHCII Thermo Scientific Donkey Anti-rat Alexa 488 Life Technologies
Ki67 Abcam Donkey Anti-rabbit Alexa 647 Life Technologies
MRC-1 R&D Systems Donkey Anti-goat Alexa 488 Life Technologies
γ-H2AX Cell Signaling Technology Donkey Anti-rabbit Alexa 555 Life Technologies
Caspase-3 Abcam Donkey Anti-rabbit Alexa 555 Life Technologies
Table 2. Immunofluorescence staining.
www.nature.com/scientificreports/
1 2Scientific RepoRts | 7: 1217  | DOI:10.1038/s41598-017-01279-1
Quantitative assessment of vessel diameter was performed by measuring at least 12 vessel diameters in 3 inde-
pendent pictures per mouse at day 20 post tumor inoculation.
RT-qPCR. mRNA analysis on siRNA treated tumor biopsies were processed as described earlier26.Total RNA 
was isolated, and PCR reaction was prepared for GAPDH as housekeeping gene, and foxP3 as gene of interest 
(Forward: ccc agg aaa gac agc aac ctt, Reverse: ttc tca caa cca ggc cac ttg, Taqman Probe: atc cta ccc act gct ggc aaa 
tgg agt c).
Correlation between T cell-associated genetic signature and LGALS1. The metagene associ-
ated with Th1, Treg or CTLs31, 33 were derived from our previously published analysis where GBM-tailored T 
cell-metagenes were established12. Th1/Treg and CTL/Treg ratios were then generated based on these datasets, 
using the TCGA GBM Exome sequencing data. The correlation of LGALS1 was analyzed with respect to these 
Th1/Treg or CTL/Treg metagene-ratios in TCGA GBM patient datasets to generate a (Pearson’s) correlation. Data 
retrieved from Project Betastasis webplatform.
Prognostic impact of T cell-associated genetic signatures and LGALS1. The differential (exome 
sequencing-derived) expression levels of Th1-associated metagene12, CTL-associated metagene12 or LGALS1 and 
associated clinical survival information (overall survival or OS) was retrieved and analyzed for the TCGA GBM 
patient data-set (n = 349)49, 50 using the Project Betastasis web-platform. These platforms stratified the respec-
tive patients on the basis of the median gene expression profile into two risk-groups i.e. high risk or low risk33. 
The respective patient risk groups were plotted with respect to OS to generate Kaplan-Meier curves using the 
Graphpad Prism software51. Hazard ratio (and its 95% confidence interval) and log-rank (Mantel-Cox) P values 
were calculated (statistical significance set at p < 0.05)33. Patients surviving beyond the follow-up thresholds were 
censored.
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